Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Retention

NCT07276763 | Not Yet Recruiting

• 1 other identifier: 2025K368
• Study Type: observational
• Target: 16,509
• Locations: 1 country
• Sites: 1

Brief Summary

A retrospective observational study to explore the impact of discontinuing GLP-1 receptor agonists for two weeks prior to upper endoscopy on the risk of gastric retention

Conditions

Gastric Retention

Keywords

Glucagon-like peptide-1 receptor agonists; Gastric Retention

Outcome Measures

Primary Outcomes (1)

• Proportion of gastric retention

  Immediately at study initiation

Study Arms (3)

No GLP-1RA group

Patients with no prescription record of GLP-1RAs, or whose most recent prescription was more than 3 months before the EGD

Other: No Intervention: Observational Cohort

GLP-1RA Continued group

Patients who met both of the following criteria: 1. Continued use of a GLP-1RA (e.g., semaglutide or dulaglutide) within 3 months prior to EGD; 2. Underwent painless EGD before August 2024, when our institution had not yet implemented restrictions on GLP-1RA use for painless endoscopy.

Other: No Intervention: Observational Cohort

GLP-1RA Held 2 Weeks group

Patients who met both of the following criteria: 1. Continued use of a GLP-1RA (e.g., semaglutide or dulaglutide) within 3 months prior to EGD; 2. Underwent painless EGD after August 2024, when institutional policy mandated that patients discontinue GLP-1RAs for at least 14 days prior to painless EGD.

Other: No Intervention: Observational Cohort

Interventions

No Intervention: Observational Cohort OTHER

No Intervention: Observational Cohort

GLP-1RA Continued group; GLP-1RA Held 2 Weeks group; No GLP-1RA group

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients who underwent elective EGD at Huadong Hospital and had complete retrievable information on medication use, medical records, and endoscopy reports

You may qualify if:

• Undergoing elective upper endoscopy
• Complete clinical information available, including endoscopy report, age, sex, BMI, history of diabetes, prior gastric surgery, and gastrointestinal symptom

You may not qualify if:

• Presence of upper gastrointestinal malignancy or obstruction
• History of gastric surgery (including ESD, gastrectomy, gastric bypass, etc.)
• Emergency endoscopy or non-elective procedures
• Missing key clinical information

Sponsors & Collaborators

• Fudan University: lead

Study Sites (1)

Huadong hospital, Fudan university

Shanghai, Shanghai Municipality, 200040, China

Location

Study Officials

• Danian Ji, M.D.

  Huadong Hospital

  STUDY DIRECTOR

Central Study Contacts

Danian Ji, M.D.

CONTACT

+86-18019094606; arctg4@163.com

Zhiyu Dong, M.D.

CONTACT

+86-18817870866; 18817870866@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Study Record Dates

• First Submitted: November 29, 2025
• First Posted: December 11, 2025
• Study Start: December 10, 2025
• Primary Completion: December 15, 2025
• Study Completion: December 15, 2025
• Last Updated: December 11, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP
• Time Frame: 1 year after completion of this study
• Access Criteria: All researchers can require the original data from principal investigator of this study (Email address: arctg4@163.com)

Locations

CN (1)